Upregulation of transmembrane 4 L6 family member 1 predicts poor prognosis in invasive breast cancer
暂无分享,去创建一个
Xinyu Zheng | F. Jin | Tingting Zhao | Qun Liu | F. Yao | Yingying Xu | Bo Chen | Yunfei Wu | Ji-guang Li | P. Xing | H. Dong
[1] F. Du,et al. SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer , 2016, Oncotarget.
[2] T. Arumugam,et al. TM4SF1 Regulates Pancreatic Cancer Migration and Invasion In Vitro and In Vivo , 2016, Cellular Physiology and Biochemistry.
[3] G. Jerusalem,et al. Triple-negative breast cancer: treatment challenges and solutions , 2016, Breast cancer.
[4] Fu Qiu,et al. TM4SF1 Promotes Proliferation, Invasion, and Metastasis in Human Liver Cancer Cells , 2016, International journal of molecular sciences.
[5] M. Patki,et al. Role of the short isoform of the progesterone receptor in breast cancer cell invasiveness at estrogen and progesterone levels in the pre- and post-menopausal ranges , 2015, Oncotarget.
[6] Yonghong Sun,et al. Role of TM4SF1 in regulating breast cancer cell migration and apoptosis through PI3K/AKT/mTOR pathway. , 2015, International journal of clinical and experimental pathology.
[7] T. Ohtsuka,et al. TM4SF1 as a prognostic marker of pancreatic ductal adenocarcinoma is involved in migration and invasion of cancer cells. , 2015, International journal of oncology.
[8] H. Cui,et al. Transmembrane-4-L-six-family-1, a potential predictor for poor prognosis, overexpressed in human glioma , 2015, Neuroreport.
[9] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[10] Kornelia Polyak,et al. Heterogeneity in breast cancer. , 2011, The Journal of clinical investigation.
[11] J. Samarut,et al. TM4SF1, a novel primary androgen receptor target gene over‐expressed in human prostate cancer and involved in cell migration , 2011, The Prostate.
[12] H. Dvorak,et al. The L6 protein TM4SF1 is critical for endothelial cell function and tumor angiogenesis. , 2009, Cancer research.
[13] C. Perou,et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] F. Berditchevski,et al. The tumour-associated antigen L6 (L6-Ag) is recruited to the tetraspanin-enriched microdomains: implication for tumour cell motility , 2008, Journal of Cell Science.
[15] Pan‐Chyr Yang,et al. CD13 (aminopeptidase N) can associate with tumor‐associated antigen L6 and enhance the motility of human lung cancer cells , 2005, International journal of cancer.
[16] J. Shih,et al. Tumor-associated antigen L6 and the invasion of human lung cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] R. Broll,et al. Diagnosis and Monitoring of Colorectal Cancer by L6 Blood Serum Polymerase Chain Reaction Is Superior to Carcinoembryonic Antigen–Enzyme-Linked Immunosorbent Assay , 2003, Diseases of the colon and rectum.
[18] G. Schieven,et al. Cloning and expression of the tumor-associated antigen L6. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[19] H. Dvorak,et al. The L 6 Protein TM 4 SF 1 Is Critical for Endothelial Cell Function and Tumor Angiogenesis , 2009 .
[20] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.